Account (3S,9R,10S,13R,14R,17R)-17-((2R,5R,E)-5,6-Dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
- Catalog No.:
- ACSEHL849
- CAS No.:
- 474-69-1
- Molecular Formula:
- C28H44O
- Molecular Weight:
- 396.66
![(3S,9R,10S,13R,14R,17R)-17-((2R,5R,E)-5,6-Dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol structure diagram](/images/productimg/no-pic.svg)
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg99%$228.00In stockInquiry
5mg99%$493.00InquiryInquiry
10mg99%$739.00In stockInquiry
25mg99%$1442.00InquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews: View Reviews
Product Information
| Product Name | (3S,9R,10S,13R,14R,17R)-17-((2R,5R,E)-5,6-Dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
|---|---|
| IUPAC Name | (3S,9R,10S,13R,14R,17R)-17-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| MDL No. | MFCD28358904 |
| Molecular Formula | C28H44O |
| Molecular Weight | 396.66 |
| SMILES | C[C@H](C(C)C)/C=C/[C@@H](C)[C@H]1CC[C@@]2([H])C3=CC=C4C[C@@H](O)CC[C@@]4(C)[C@]3([H])CC[C@]12C |
| InChI Key | DNVPQKQSNYMLRS-YAPGYIAOSA-N |
| Synonym | 9-beta,10-alpha-ergosta-5,7,22-trien-3-beta-ol;Ergosta-5,7,22-trien-3-ol, (3.beta.,9.beta.,10.alpha.,22E)-;(9β,10α,22E)-Ergosta-5,7,22-trien-3β-ol;Einecs 207-487-0;(3beta,9beta,10alpha,22E)-Ergosta-5,7,22-trien-3-ol;Ergocalciferol EP Impurity C (Lumisterol);Ergosta-5,7,22-trien-3-ol, (3β,9β,10α,22E)-;(3S,9R,10S,13R,14R,17R)-17-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| CAS No. | 474-69-1 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302-H413
- Precautionary Statement(s)
- P264-P270-P273-P301+P312-P330-P501
Synthetic Route by SureRoute
(3S,9S,10R,13R,14R,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
(3S,9S,10R,13R,14R,17R)-17-((2R,5R,E)-5,6-Dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
(3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-((R)-6-methyl-5-methyleneheptan-2-yl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol